Gert De Meerleer is currently head-of-clinics at the department of Radiation Oncology at University Hospital Leuven. His main field of interest is urologic oncology with a focus on implementing modern radiation technology in the treatment of prostate cancer, kidney cancer, testicular cancer and to a lesser extent, bladder cancer. He has pioneered the implementation of stereotactic body radiotherapy in the treatment of oligometastatic prostate cancer, which has led to a paradigm shift in the treatment of these patients. Gert De Meerleer successfully defended his PhD in 2000. In this PhD, he described the implementation of intensity-modulated radiotherapy in the treatment of prostate cancer. Since then, he (co-)promoted several other PhD’s, most of them dealing with the implementation of intensity-modulated radiotherapy (including arc therapy) in the treatment of urological and, to a lesser extent, gynaecologic malignancies. He is an active member of the multidisciplinary working group of urological malignancies at Leuven University Hospital. He has also (co-)authored more than 150 A1 publications, most of them in the field of urological oncology, co-edited several booklets on prostate cancer and was granted several times and by different organizations (FWO, VLK, Stichting tegen Kanker, Movember) for his scientific research. He is full professor at Leuven (KUL), with a main focus on scientific research in the treatment of urologic malignancies, with a special focus on the interaction of stereotactic body radiotherapy and systemic treatments. He pioneered the implementation of metastasis-directed therapy in the treatment of oligometastatic urologic malignancies. Gert De Meerleer is co-president of the Belgian Radiotherapy Awareness and Visibility Organization (BRAVO), board member of Scientific Summits, a high-level scientific Belgian organization and a member of the scientific jury of the “Federation against Cancer”. He is an experienced international speaker at urologic and oncologic congresses, a reviewer for several international cancer organizations and high-ranked journals and is also involved in teaching within Belgium and Europe.